The firms plan to integrate Curetis' Unyvero sample prep system and MGI's NGS to create a microbial pathogens and antibiotic resistance detection workflow.
The firm has used its proximity ligation method to interpret metagenomic sequence data from a human fecal sample, unraveling new and known genomes in the mix.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service.
Among other plans, CosmosID is using the funds to prep its platform for clinical use including running validation studies with partner hospitals.
Researchers generated a near complete genome sequence for a 5,300 year old Helicobacter pylori strain found in the gut of Ötzi, the Tyrolean Iceman.
The researchers demonstrated that the panel could identify pathogens in mock clinical samples even at very low levels, while unbiased sequencing could not.
The Toronto-based firm will use the funds to finance ongoing molecular diagnostics product development and expansion.
The Virginia-based firm will use the funds to build out its next-generation sequencing data analytics for pathogen identification and surveillance.
The funding comes as part of the agency's Advanced Molecular Detection initiative, which is using the technologies to help address infectious disease outbreaks.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.